{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:24:40Z","timestamp":1774085080159,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[1998,6,1]],"date-time":"1998-06-01T00:00:00Z","timestamp":896659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1998,6,1]],"date-time":"1998-06-01T00:00:00Z","timestamp":896659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[1998,6]]},"DOI":"10.1023\/a:1005948722912","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T00:10:48Z","timestamp":1040515848000},"page":"233-239","source":"Crossref","is-referenced-by-count":39,"title":["New aspects of immunotherapy of leptomeningeal metastasis"],"prefix":"10.1007","volume":"38","author":[{"given":"Ulrich","family":"Herrlinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schabet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"159849_CR1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0147-0272(88)80001-1","volume":"12","author":"WA Bleyer","year":"1988","unstructured":"Bleyer WA, Byrne TN: Leptomeningeal cancer in leukemia and solid tumors. Curr Probl Cancer 12: 181\u2013238, 1988","journal-title":"Curr Probl Cancer"},{"key":"159849_CR2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0165-0173(95)00010-0","volume":"21","author":"M Weller","year":"1995","unstructured":"Weller M, Fontana A: The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-?, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev 21: 128\u2013151, 1995","journal-title":"Brain Res Rev"},{"key":"159849_CR3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF01049981","volume":"17","author":"M Tada","year":"1993","unstructured":"Tada M, de Tribolet N: Recent advances in immunobiology of brain tumors. J Neuro-Oncol 17: 261\u2013271, 1993","journal-title":"J Neuro-Oncol"},{"key":"159849_CR4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00205758","volume":"27","author":"EA Grimm","year":"1988","unstructured":"Grimm EA, Crump III WL, Durett A, Hester JP, Lagoo-Denadalayan S, Owen-Schaub L: TGF-beta inhibits the in vitro induction of lymphokine-activated killing. Cancer Immunol Immunother 27: 53\u201338, 1988","journal-title":"Cancer Immunol Immunother"},{"key":"159849_CR5","first-page":"1386","volume":"52","author":"TH Inge","year":"1992","unstructured":"Inge TH, Hoover SK, Suesskind BM, Barrett SK, Bear HD: Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor ?1. Cancer Res 52: 1386\u20131392, 1992","journal-title":"Cancer Res"},{"key":"159849_CR6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jnnp.54.3.260","volume":"54","author":"RP Moseley","year":"1991","unstructured":"Moseley RP, Benjamin JC, Ashpole RD, Sullivan NM, Bullimore JA, Coakham HB, Kemshead JT: J Neurol Neurosurg Psychiatry 54: 260\u2013265, 1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"159849_CR7","first-page":"293","volume-title":"Cancer Principles and Practice of Oncology","author":"SA Rosenberg","year":"1993","unstructured":"Rosenberg SA: Principles and applications of biologic therapy. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer Principles and Practice of Oncology. 4th edition. J.B. Lippincott Co., Philadelphia, Pennsylvania 293\u2013324, 1993","edition":"4th edition"},{"key":"159849_CR8","first-page":"249","volume":"21","author":"KA Jaeckle","year":"1994","unstructured":"Jaeckle KA: Immunotherapy of malignant gliomas. Sem Oncol 21: 249\u2013259, 1994","journal-title":"Sem Oncol"},{"key":"159849_CR9","first-page":"4338","volume":"50","author":"J Tzeng","year":"1990","unstructured":"Tzeng J, Barth RF, Clendenon NR, Gordon W: Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin-2. Cancer Res 50: 4338\u20134343, 1990","journal-title":"Cancer Res"},{"key":"159849_CR10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3171\/jns.1994.80.1.0090","volume":"80","author":"FP Holladay","year":"1994","unstructured":"Holladay FP, Choudhuri R, Heitz T, Wood GW: Generation of cytotoxic immune responses during the progression of a rat glioma. J Neurosurg 80: 90\u201396, 1994","journal-title":"J Neurosurg"},{"key":"159849_CR11","first-page":"A1332","volume":"36","author":"GW Wood","year":"1995","unstructured":"Wood GW, Holladay FP, Heitz-Turner T, Bayer W: Treatment of recurrent malignant astrocytoma by reoperation, active immunization and cellular immunotherapy. Proc Annu Meet Am Assoc Cancer Res 36: A1332, 1995 (Abstract)","journal-title":"Proc Annu Meet Am Assoc Cancer Res"},{"key":"159849_CR12","first-page":"1123","volume":"52","author":"J List","year":"1992","unstructured":"List J, Moser RP, Steuer M, Loudon WG, Blacklock JB, Grimm EA: Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor ?, interleukin 1?, interleukin 6, ?-interferon, and soluble interleukin 2 receptor (MW 55,000 Protein). Cancer Res 52: 1123\u20131128, 1992","journal-title":"Cancer Res"},{"key":"159849_CR13","first-page":"399","volume":"3","author":"R Martin","year":"1992","unstructured":"Martin R, Schwulera U, Menke G, Rudolph W, Buch K, Fasold H, Lissner R, Thrun A, Krauseneck P, Bogdahn U: Interleukin-2 and blood brain barrier in cats: pharmacokinetics and tolerance following intrathecal and intravenous administration. Eur Cytokine Netw 3: 399\u2013406, 1992","journal-title":"Eur Cytokine Netw"},{"key":"159849_CR14","first-page":"189","volume":"4","author":"M R\u00f6sener","year":"1993","unstructured":"R\u00f6sener M, Schwulera U, Menke G, Thrun A, Lissner R, Krauseneck P, Bogdahn U, Martin R: Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural interleukin-2: a phase I trial. Eur Cytokine Netw 4: 189\u2013195, 1993","journal-title":"Eur Cytokine Netw"},{"key":"159849_CR15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3171\/jns.1988.69.1.0029","volume":"69","author":"SC Saris","year":"1988","unstructured":"Saris SC, Rosenberg SA, Friedman RB, Rubin JT, Barba D, Oldfield EH: Penetration of recombinant interleukin-2 across the blood-cerebro-spinal barrier. J Neurosurg 69: 29\u201334, 1988","journal-title":"J Neurosurg"},{"key":"159849_CR16","first-page":"2393","volume":"13","author":"S Miyatake","year":"1986","unstructured":"Miyatake S, Yamashita J, Tokuriki Y, Yamasaki T, Nisihara T, Handa Y, Sugama K, Tsubai F, Hazama T, Handa H: Pharmacokinetics and toxicity of intrathecal administration of recombinant interleukin-2. Gan To Kagaku Ryoho 13: 2393\u20132398, 1986","journal-title":"Gan To Kagaku Ryoho"},{"key":"159849_CR17","first-page":"6302","volume":"50","author":"JA Stewart","year":"1990","unstructured":"Stewart JA, Bellinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF: Phase I trial of intraperitoneal recombinant interleukin-2\/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 50: 6302\u20136310, 1990","journal-title":"Cancer Res"},{"key":"159849_CR18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00002371-199301000-00007","volume":"13","author":"WE Samlowski","year":"1993","unstructured":"Samlowski WE, Park KJ, Galinsky RE, Ward JH, Schumann GB: Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother 13: 49\u201354, 1993","journal-title":"J Immunother"},{"key":"159849_CR19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/00207459408986024","volume":"77","author":"A Salmaggi","year":"1994","unstructured":"Salmaggi A, Dufour A, Silvani A, Ciusani E, Nespolo A, Boiardi A: Immunological fluctuations during intrathecal immunotherapy in three patients affected by CNS tumors disseminating via CSF. Intern J Neurosci 77: 117\u2013125, 1994","journal-title":"Intern J Neurosci"},{"key":"159849_CR20","first-page":"67","volume":"21","author":"M Schabet","year":"1994","unstructured":"Schabet M, Herrlinger U, Buchholz R: CSF reaction pattern and neurotoxicity after intrathecal application of TNF-??and IFN-?, or IL-2. J Neuro-Oncol 21: 67, 1994a (Abstract)","journal-title":"J Neuro-Oncol"},{"key":"159849_CR21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00165475","volume":"27","author":"U Herrlinger","year":"1996","unstructured":"Herrlinger U, Buchholz R, Jachimczak P, Schabet M: Intrathecal treatment of C6 glioma leptomeningeal metastasis in Wistar rats with interleukin-2. J Neuro-Oncol 27: 193\u2013203, 1996","journal-title":"J Neuro-Oncol"},{"key":"159849_CR22","first-page":"A968","volume":"12","author":"R Hayes","year":"1993","unstructured":"Hayes R, Moore E, Pierz DM, Chen D, DaRosso R, Nirenberg A, Allen J: Interleukin-2 (IL-2)-inducible lymphokineactivated killer (LAK) activity arising in blood following IL-2\/LAK therapy into the CSF compartment. Proc Annu Meet Am Soc Clin Oncol 12: A968, 1993","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"159849_CR23","first-page":"A528","volume":"12","author":"J Allen","year":"1993","unstructured":"Allen J, Hayes R, DaRosso R, Nirenberg A, Moore E, Pierz D: Intraventricular interleukin-2 (IL-2)\/lymphokine activated killer (LAK) cells for leptomeningeal metastases (LM) in pediatric brain tumors. Proc Annu Meet Am Soc Clin Oncol 12: A528, 1993","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"159849_CR24","first-page":"117","volume":"43","author":"RP Moser","year":"1991","unstructured":"Moser RP, Bruner JM, Grimm EA: Biologic therapy for brain tumors. Cancer Bull 43: 117\u2013126, 1991","journal-title":"Cancer Bull"},{"key":"159849_CR25","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4049\/jimmunol.142.3.1036","volume":"142","author":"J Jaaskelainen","year":"1989","unstructured":"Jaaskelainen J, Kalliomaki P, Paetau A, Timonen T: Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets. J Immunol 142: 1036\u20131045, 1989","journal-title":"J Immunol"},{"key":"159849_CR26","first-page":"436","volume":"4","author":"M Schabet","year":"1994","unstructured":"Schabet M, Ohneseit P, Herrlinger U, Buchholz R: Intrathecal treatment of B16-F10 melanoma leptomeningeal metastasis (LM) in nude rats with MTX, ACNU or the combination of IFN-gamma and TNF-alpha. Brain Pathol 4: 436, 1994b (Abstract)","journal-title":"Brain Pathol"},{"key":"159849_CR27","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.4049\/jimmunol.142.6.2133","volume":"142","author":"ASF Chong","year":"1989","unstructured":"Chong ASF, Scuderi P, Grimes WJ, Hersh EN: Tumor targets stimulate IL-2 activated killer cells to produce interferon-??and tumor necrosis factor. J Immunol 142: 2133\u20132139, 1989","journal-title":"J Immunol"},{"key":"159849_CR28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1084\/jem.173.3.647","volume":"173","author":"RJ Barth","year":"1991","unstructured":"Barth RJ, Mule JJ, Spiess PJ, Rosenberg SA: Interferon-??and tumor necrosis factor have a role in tumor regression mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173: 647\u2013658, 1991","journal-title":"J Exp Med"},{"key":"159849_CR29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3171\/jns.1990.72.1.0102","volume":"72","author":"IE McCutcheon","year":"1990","unstructured":"McCutcheon IE, Baranco RA, Katz DA, Saris SC: Adoptive immunotherapy of intracerebral metastases in mice. J Neurosurg 72: 102\u2013109, 1990","journal-title":"J Neurosurg"},{"key":"159849_CR30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3171\/jns.1992.76.3.0513","volume":"76","author":"SS Saris","year":"1992","unstructured":"Saris SS, Spiess A, Lieberman DM, Shan Lin, Walbridge S, Oldfield EH: Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 76: 513\u2013519, 1992","journal-title":"J Neurosurg"},{"key":"159849_CR31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3171\/jns.1992.77.5.0757","volume":"77","author":"FP Holladay","year":"1992","unstructured":"Holladay FP, Heitz T, Wood GW: Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J Neurosurg 77: 757\u2013762, 1992","journal-title":"J Neurosurg"},{"key":"159849_CR32","first-page":"A1307","volume":"14","author":"NE Papadopoulos","year":"1995","unstructured":"Papadopoulos NE, Moser RP, Grimm E, Gerber D, Myers C, Leavens M, McCutcheon I, Leeds NE, Kumar AJ, Forman A, Legha S, Benjamin RS: Intrathecal use of recombinant interleukin-2 (rIL-2) in the treatment of leptomeningeal disease (LMD) from metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 14: A1307, 1995","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"159849_CR33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01406615","volume":"94","author":"Y Okamoto","year":"1988","unstructured":"Okamoto Y, Shimizu K, Tamura K, Miyao Y, Yamada M, Matsui Y, Tsuda N, Takimoto H, Hayakawa T, Mogami H: An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien) 94: 47\u201352, 1988","journal-title":"Acta Neurochir (Wien)"},{"key":"159849_CR34","first-page":"991","volume":"41","author":"K Shimizu","year":"1989","unstructured":"Shimizu K, Tamura K, Yamada M, Okamoto Y, Miyao Y, Park K, Matsui Y, Hayakawa T, Takimoto H, Mogami H: Adoptive immunotherapy in patients with medulloblastoma by LAK cells. No To Shinkei 41: 991\u2013995, 1989","journal-title":"No To Shinkei"},{"key":"159849_CR35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3171\/jns.1987.66.4.0519","volume":"66","author":"K Shimizu","year":"1987","unstructured":"Shimizu K, Okamoto Y, Miyao Y, Yamada M, Ushio Y, Hayakawa T, Ikeda H, Mogami H: Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. J Neurosurg 66: 519\u2013521, 1987","journal-title":"J Neurosurg"},{"key":"159849_CR36","first-page":"1078","volume":"34","author":"A Silvani","year":"1994","unstructured":"Silvani A, Salmaggi A, Parmiani G, Boiardi A: Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report. Neurosurg 34: 1078\u20131081, 1994","journal-title":"Neurosurg"},{"key":"159849_CR37","first-page":"61","volume":"3","author":"EAMT Obbens","year":"1985","unstructured":"Obbens EAMT, Feun LG, Leavens ME et al.: Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies. J Neuro-Oncol 3: 61\u201367, 1985","journal-title":"J Neuro-Oncol"},{"key":"159849_CR38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/1097-0142(19910701)68:1<88::AID-CNCR2820680118>3.0.CO;2-5","volume":"68","author":"CA Meyers","year":"1991","unstructured":"Meyers CA, Obbens EAMT, Scheibel RS, Moser RP: Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 68: 88\u201392, 1991","journal-title":"Cancer"},{"key":"159849_CR39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00177842","volume":"8","author":"RE Merchant","year":"1990","unstructured":"Merchant RE, Ellison ED, Young HF: Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. J Neuro-Oncol 8: 173\u2013188, 1990","journal-title":"J Neuro-Oncol"},{"key":"159849_CR40","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0090-3019(91)90079-O","volume":"35","author":"JJ Heimans","year":"1991","unstructured":"Heimans JJ, Wagstaff J, Schreuder WO, Wolbers JG, Baars JW, Polman CH, Scharenberg JG, Scheper RJ, Palmer PA, Franks CR: Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2. Surg Neurol 35: 244\u2013247, 1991","journal-title":"Surg Neurol"},{"key":"159849_CR41","first-page":"5618","volume":"46","author":"MZ Papa","year":"1986","unstructured":"Papa MZ, Vetto JT, Ettinghausen SE, Mule JJ, Rosenberg SA: Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin-2 in mice. Cancer Res 46: 5618\u20135623, 1986","journal-title":"Cancer Res"},{"key":"159849_CR42","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1523\/JNEUROSCI.13-08-03368.1993","volume":"13","author":"U Hanisch","year":"1993","unstructured":"Hanisch U, Seto D, Quirion R: Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2. J Neurosci 13: 3368\u20133374, 1993","journal-title":"J Neurosci"},{"key":"159849_CR43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0006-8993(94)90006-X","volume":"643","author":"S Zalcman","year":"1994","unstructured":"Zalcman S, Green-Johnson JM, Murray L et al.: Cytokinespecific central monoamine alterations induced by interleukin-1,-2, and-6. Brain Res 643: 40\u201349, 1994","journal-title":"Brain Res"},{"key":"159849_CR44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF01050073","volume":"15","author":"CA Meyers","year":"1993","unstructured":"Meyers CA, Yung WKA: Delayed neurotoxicity of intraventricular interleukin-2: a case report. J Neuro-Oncol 15: 265\u2013267, 1993","journal-title":"J Neuro-Oncol"},{"key":"159849_CR45","first-page":"1146","volume":"323","author":"CJ Vecht","year":"1990","unstructured":"Vecht CJ, Keohane C, Menon RS, Henzen-Logmans SC, Punt CJA, Stoter G: Acute fatal leukoencephalopathy after interleukin-2 therapy. N Engl J Med 323: 1146\u20131147, 1990","journal-title":"N Engl J Med"},{"key":"159849_CR46","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1172\/JCI117462","volume":"94","author":"M Weller","year":"1994","unstructured":"Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas\/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation by cytokines. J Clin Invest 94: 954\u2013964, 1994","journal-title":"J Clin Invest"},{"key":"159849_CR47","first-page":"345","volume":"4","author":"U Herrlinger","year":"1997","unstructured":"Herrlinger U, Kramm CM, Johnston KM, Louis DN, Reznikoff G, Dranoff G, Breakefield XO, Yu JS: Vaccination for experimental gliomas using GM-CSF transduced glioma cells. Cancer Gene Ther 4: 345\u2013352, 1997","journal-title":"Cancer Gene Ther"},{"key":"159849_CR48","first-page":"1828","volume":"56","author":"H Wakimoto","year":"1996","unstructured":"Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K Hamada H: Intensified antitumor immunity by a cancer vaccine that prouces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 56: 1828\u20131833, 1996","journal-title":"Cancer Res"},{"key":"159849_CR49","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1089\/hum.1997.8.9-1065","volume":"8","author":"JS Yu","year":"1997","unstructured":"Yu JS, Burwick JA, Reznikoff G, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor melanoma cells. Hum Gene Ther 8: 1065\u20131072, 1997","journal-title":"Hum Gene Ther"},{"key":"159849_CR50","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.93.7.2909","volume":"93","author":"H Fahkrai","year":"1996","unstructured":"Fahkrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93: 2909\u20132914, 1996","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005948722912.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1005948722912\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005948722912.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T09:08:27Z","timestamp":1749632907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1005948722912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":50,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["159849"],"URL":"https:\/\/doi.org\/10.1023\/a:1005948722912","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6]]}}}